SHR 6390Alternative Names: SHR 6390
Latest Information Update: 21 Apr 2016
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malignant melanoma
Most Recent Events
- 19 Feb 2016 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Late-stage disease) in China (NCT02684266)
- 01 Jan 2016 Phase-I clinical trials in Malignant melanoma (Late-stage disease, Inoperable/Unresectable) in China (PO) (NCT02671513)
- 30 Dec 2015 Preclinical trials in Malignant melanoma in China (PO)